Insight Molecular Diagnostics (IMDX)
NASDAQ:IMDX
Want to see IMDX full AI Analyst Report?
IMDX Stock Chart & Stats
$3.17
--
Market closed
$3.17
--
Day’s Range― - ―
52-Week Range$2.33 - $8.51
Previous CloseN/A
VolumeN/A
Average Volume (3M)42.75K
Market Cap
$180.50M
Enterprise Value$117.66M
Total Cash (Recent Filing)$28.20M
Total Debt (Recent Filing)$3.07M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Aug 06, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.51
Shares Outstanding32,290,170
10 Day Avg. Volume47,668
30 Day Avg. Volume42,754
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-7.26
Price to Sales (P/S)56.37
P/FCF Ratio-9.01
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue60.37
Enterprise Value/Gross Profit310.05
Enterprise Value/Ebitda-2.59
Forecast
1Y Price Target
$10.50Price Target Upside231.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.95
Revenue Forecast (FY)$2.59M
Bulls Say, Bears Say
Bulls Say
FDA Submission And Active EngagementAn FDA submission with active, productive engagement materially de-risks U.S. market access. Continued review interaction and the expectation of first U.S. orders later this year create a clear path from development to revenue, supporting commercialization planning and partner/customer discussions over the coming months.
ISO 13485 Certification And Registry TractionISO 13485 certification underpins quality systems required for medical-device diagnostics and eases regulatory submissions and customer acceptance. Simultaneous registry growth across transplant centers drives clinical validation and referral pathways, strengthening adoption prospects and reimbursement conversations over time.
Medicare Reimbursement BenchmarkAn established Medicare reimbursement rate provides a concrete, durable payment anchor that supports pricing, hospital economics, and commercial discussions. This reduces a major commercialization barrier in the U.S., improving the economic case for adoption and facilitating longer-term revenue predictability once volumes scale.
Bears Say
Severe Cash Burn And Negative Free Cash FlowPersistent multi‑million-dollar operating and free cash flow deficits mean the business cannot self-fund growth and relies on external capital. That dynamic compresses strategic flexibility, raises dilution and refinancing risk, and can constrain commercialization and instrument placement timelines absent additional financing.
Negative Stockholders' EquityNegative equity reflects cumulative losses and weak retained capital, limiting borrowing capacity and raising counterparty concerns. Over a multi‑month horizon this elevates refinancing and dilution risk, potentially increasing cost of capital and complicating partnerships or larger commercial rollouts.
Commercialization Constrained By Instrument PlacementRelying on instrument placement as a gating factor limits how quickly kit volume and ASPs can scale. Combined with very low near‑term revenue guidance and initial sub-target margins, this constraint prolongs the time to profitable unit economics and delays meaningful cash generation from commercial sales.
Insight Molecular Diagnostics News
IMDX FAQ
What was Insight Molecular Diagnostics’s price range in the past 12 months?
Insight Molecular Diagnostics lowest stock price was $2.33 and its highest was $8.51 in the past 12 months.
What is Insight Molecular Diagnostics’s market cap?
Insight Molecular Diagnostics’s market cap is $180.50M.
When is Insight Molecular Diagnostics’s upcoming earnings report date?
Insight Molecular Diagnostics’s upcoming earnings report date is Aug 06, 2026 which is in 40 days.
How were Insight Molecular Diagnostics’s earnings last quarter?
Insight Molecular Diagnostics released its earnings results on May 13, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.262 by $0.142.
Is Insight Molecular Diagnostics overvalued?
According to Wall Street analysts Insight Molecular Diagnostics’s price is currently Undervalued.
Does Insight Molecular Diagnostics pay dividends?
Insight Molecular Diagnostics does not currently pay dividends.
What is Insight Molecular Diagnostics’s EPS estimate?
Insight Molecular Diagnostics’s EPS estimate is -0.24.
How many shares outstanding does Insight Molecular Diagnostics have?
Insight Molecular Diagnostics has 32,290,170 shares outstanding.
What happened to Insight Molecular Diagnostics’s price movement after its last earnings report?
Insight Molecular Diagnostics reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.262. Following the earnings report the stock price went up 25.882%.
Which hedge fund is a major shareholder of Insight Molecular Diagnostics?
Currently, no hedge funds are holding shares in IMDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insight Molecular Diagnostics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (231.23% Upside)
$10.50 (231.23% Upside)
Hedge Fund Trend
Decreased
By 44.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.7M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.71%
12-Months-Change
Fundamentals
Return on Equity
380.80%
Trailing 12-Months
Asset Growth
-33.02%
Trailing 12-Months
Company Description
Insight Molecular Diagnostics
OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.
IMDX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents clear operational and regulatory progress (FDA submission engagement, ISO certification, registry momentum, pricing validation, TAM affirmation, emerging head-to-head data and organ expansion), balanced against near-term financial pressures (Q2 cash burn >$9M, very low near-term revenue ~$0.25M), commercialization constraints (instrument placement), and timing uncertainty in Europe and FDA review details. Management provided concrete targets for margins, cost structure, and runway management and expects cash burn to decline in the back half of the year. Overall, the call signals meaningful de-risking and commercialization preparation while acknowledging near-term financial drag.View all IMDX earnings summariesIMDX Stock 12 Month Forecast
Average Price Target
$10.50
▲(231.23% Upside)
Technical Analysis
Ownership Overview
80.04% Insiders
1.90% Mutual Funds
4.15% Other Institutional Investors
12.17% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---